Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

NVP-LCQ195

Catalog No: tcsc0840

Available Sizes

Size: 5mg

Size: 10mg

Specifications

CAS No:
902156-99-4

Formula:
$C_{17}H_{19}Cl_2N_5O_4S$

Pathway:
Cell Cycle/DNA Damage

Target:
CDK

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Alternative Names:
LCQ-195;AT9311

Observed Molecular Weight:
460.33

Product Description

NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

IC50 Value: 1 nM(CDK5/p25 and CDK5/p35); 2 nM(CDK1/cyclinB and CDK2/cyclinA); 5 nM(CDK2/cyclinE); 42 nM(CDK3/cyclinE)

Target: CDKs

LCQ195 induced cell cycle arrest and eventual apoptotic cell death of MM cells, even at sub-lmol/l concentrations, spared non-malignant cells, and overcame the protection conferred to MM cells by stroma or cytokines of the bone marrow milieu. In MM cells, LCQ195 triggered decreased amplitude of transcriptional signatures associated with oncogenesis, drug resistance and stem cell renewal, including signatures of activation of key transcription factors for MM cells e.g. myc, HIF-1a, IRF4. Bortezomib-treated MM patients whose tumours had high baseline expression of genes suppressed by

LCQ195 had significantly shorter progression-free and overall survival than those with low levels of these transcripts in their MM cells. These observations provide insight into the biological relevance of multi-targeted CDK inhibition in MM.